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ABSTRACT
Background
Skin atrophy is a common manifestation of aging and is frequently accompanied by
ulceration and delayed wound healing. With an increasingly aging patient population,
management of skin atrophy is becoming a major challenge in the clinic, particularly in light of
the fact that there are no effective therapeutic options at present.
Methods and Findings
Atrophic skin displays a decreased hyaluronate (HA) content and expression of the major cell-
surface hyaluronate receptor, CD44. In an effort to develop a therapeutic strategy for skin
atrophy, we addressed the effect of topical administration of defined-size HA fragments (HAF)
on skin trophicity. Treatment of primary keratinocyte cultures with intermediate-size HAF (HAFi;
50,000–400,000 Da) but not with small-size HAF (HAFs; ,50,000 Da) or large-size HAF (HAFl;
.400,000 Da) induced wild-type (wt) but not CD44-deficient (CD44
 / )k e r a t i n o c y t e
proliferation. Topical application of HAFi caused marked epidermal hyperplasia in wt but not
in CD44
 /  mice, and significant skin thickening in patients with age- or corticosteroid-related
skin atrophy. The effect of HAFi on keratinocyte proliferation was abrogated by antibodies
against heparin-binding epidermal growth factor (HB-EGF) and its receptor, erbB1, which form
a complex with a particular isoform of CD44 (CD44v3), and by tissue inhibitor of
metalloproteinase-3 (TIMP-3).
Conclusions
Our observations provide a novel CD44-dependent mechanism for HA oligosaccharide-
induced keratinocyte proliferation and suggest that topical HAFi application may provide an
attractive therapeutic option in human skin atrophy.
The Editors’ Summary of this article follows the references.
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Skin atrophy is a frequent and clinically relevant manifes-
tation of aging, often complicated by ulceration and impaired
wound healing. Experimental evidence suggests that defective
function of the principal cell-surface hyaluronate (HA)
receptor CD44 [1,2], which is associated with impaired HA
metabolism, may underlie the pathogenesis of this disorder
[3]. HA is the most abundant glycosaminoglycan in cutaneous
tissues [4] and is deposited in the extracellular matrix as a
high-molecular-weight polymer. Cleavage of the HA polymer
during tissue remodeling gives rise to lower-molecular-weight
fragments that elicit a variety of CD44-mediated cellular
responses, including proliferation, migration, and cytokine
synthesis. Increasing evidence suggests that cellular responses
elicited by HA depend on the size of the HA oligosaccharides
as well as on the responding cell type [5,6]. Thus, HA
f r a g m e n t s( H A F ) ,b u tn o tn a t i v eH Ap o l y m e ro rH A
disaccharides, could activate Ras and PKCf in tumor cells in
a CD44-dependent fashion [7]; 35,000- to 280,000-Da HA
preparations were shown to stimulate CD44-mediated che-
mokine gene expression in alveolar macrophages [8]; HA
oligosaccharides have been reported to induce a toll-like
receptor–mediated response in endothelial cells [9]; and only
tetra- and hexasaccharide HA fragments have been observed
to induce immunophenotypic maturation of human den-
dritic cells [10].
Cellular responses to HA are primarily mediated by CD44,
the most broadly expressed cell-surface HA receptor whose
function is regulated at transcriptional, translational, and
post-translational levels. Expression levels, variant isoform
selection, and glycosylation all play an important role in the
ability of CD44 to bind HA [11,12]. Because of its polymeric
structure, HA can crosslink several CD44 molecules on the
surface of a cell, an effect that is believed to be essential in
triggering proliferative, invasive, and promigratory signals
[11]. HA-mediated CD44 clustering can have a variety of
effects, depending, at least in part, on the CD44 isoform that
is implicated in HA binding. Thus, in mouse mammary and
uterine epithelia, HA can induce heparan sulfate–bearing
variants of CD44 (CD44v3) to recruit a cell-surface complex
that includes matrix metalloproteinase 7 (MMP-7), heparin-
binding epidermal-like growth factor (HB-EGF) precursor
HB-EGF (pro-HB-EGF), and erbB4 [13]. MMP-mediated HB-
EGF activation within this complex promotes epithelial cell
survival in the lactating mammary gland and postpartum
uterus [13]. CD44v3 isoforms are expressed in skin keratino-
cytes, where HA has been shown to regulate keratinocyte
proliferation [3]. CD44 in turn appears to play an important
role in maintaining HA homeostasis in skin [3], and its levels
appear to correlate with skin trophicity. Thus, decreased
epidermal CD44 expression is associated with the patho-
g e n e s i so fa na t r o p h i cs k i nd i s o r d e rk n o w na sl i c h e n
sclerosus et atrophicus [14]. Conversely, epidermal hyper-
plasia induced by topical administration of retinoids in
mouse skin is accompanied by increased CD44 and HA
synthase (HAS) expression with a concomitant increase in
HA deposition [15]. To elucidate the mechanism whereby HA
might induce keratinocyte proliferation, and to determine
the response of the epidermis to its application in vivo, we
examined the effect of HAF of varying size on in vitro–
cultured mouse keratinocyte growth, and skin trophicity of
DBA/1 wild-type (wt) and CD44
 /  mice SKH1 hairless mice,
as well as normal and atrophic human skin. Our observations
indicate that HAF of 50,000–400,000 Da, deﬁned as inter-
mediate-size HAF (HAFi), induce keratinocyte proliferation
and skin hyperplasia by a CD44-dependent mechanism that
requires proteolytic activation of HB-EGF and engagement
of erbB1.
Methods
Preparation of HAFi
HA from rooster comb (IAL) for clinical application was
provided by Transbussan (http://www.transbussan.com).
Three types of HA from IAL were used: (1) HAFl: high-
molecular-weight HA (IAL); (2) HAFi: fragmentation prod-
ucts of HA of medium size (50,000–400,000 Da) was prepared
using a Braun soniﬁer (http://www.bbraunusa.com) for 30 min
at 400 W on ice. The fragments were then separated on a
Sephacryl S-400 HR 4 3 80 cm size exclusion gel ﬁltration
column (Pharmacia Diagnostics, http://www.phadia.com). The
column was calibrated using Pullulan standards (Showa-
Denko, http://www.showadenko.com) from 20,000 to 800,000
Da. Fractions (100) of 10 ml each were collected from the
column with a Frac 100 fraction collector (Pharmacia, http://
www.pharmacia.com) at a ﬂow rate of 1 ml/min. The HA
concentration of each sample was determined by a colori-
metric dosage according to a BCA-reducing sugar assay, and
an elution proﬁle for the fragments was obtained. The
fractions corresponding to the 50,000–400,000 Da were
pooled, dialyzed against distilled water, and lyophilized. (3)
HAFs: small fragmentation products of HA (1,000–50,000 Da)
were generated by enzymatic digestion of high-molecular-
weight HA with bovine testis hyaluronidase (Sigma, http://
www.sigmaaldrich.com) for 1 h at 37 8C in 0.1 M sodium
acetate buffer, 0.15 M NaCl, and 1mM EDTA (pH 5.0), and
lyophilized. The fragments were separated by 15% polyacry-
lamide gel (TBS) electrophoresis and visualized with an alcian
blue and silver staining. The HAF of different sizes were
prepared in the form of cream by the same vehicle.
Treatment of Mice
Groups of ﬁve adult (.3 mo-old) SKH1 hairless, DBA/1
(The Jackson Laboratory, http://www.jax.org), or CD44-deﬁ-
cient (CD44
 / ) mice [13] were used. HAF (0.2%) or vehicle
cream samples of 0.5 g were applied twice daily for 3 d to the
dorsal skin of SKH1 hairless, DBA/1, or CD44
 /  mice.
Biotinylated 0.2% HAF (Carbomer, http://www.carbomer.
com) in Liposol (Sigene, http://www.sigene.com) was applied
twice daily for 3 d on the back skin of SKH1 hairless mice.
TPA (Sigma; 0.005% solution in acetone) was applied twice
daily for 3 d to the dorsal skin of DBA/1 or CD44
 /  mice.
Animals were killed 2 h after the last application. All
experiments were approved by the Ethical Commission on
Animal Experimentation of the University of Geneva and the
Cantonal Veterinary Ofﬁce of Geneva.
Treatment of Healthy Participants and Patients
Seven healthy young adults (seven males) between 19 and
32 y (mean age, 25.5 y), ten healthy women in menopause
without hormone replacement therapy between 55 and 65 y
(mean age, 60 y), three patients with advanced age-related
skin atrophy (two females, one male) between 60 and 88 y
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prolonged use of oral corticosteroids for rheumatoid arthritis
(three females) between 74 and 86 y (mean age, 81 y) were
included in this study after obtaining informed consent.
Clinical studies were conducted with the authorization and
according to the guidelines of Ethical Commission on Human
Research of the University Hospital of Geneva. HAFi (1%) or
vehicle cream samples of 0.5 g were applied twice daily for 1
mo on the posterior side of the right or left arm, respectively.
Histology
Dorsal skin samples were ﬁxed in 10% phosphate-buffered
formaldehyde, embedded in parafﬁn, and processed for
histological analysis. Sections were cut at 5 lm, mounted
onto slides, and stained with hematoxylin-eosin, Sirius red,
and van Gieson elastin according to standard procedures.
Staining of Skin Sections for CD44, CD44v3, HA-Binding
Protein, Ki-67, Biotinylated HAF, Vimentin, Filaggrin,
Loricrin, K14, and CD31
Parafﬁn-embedded sections (5 lm) were mounted onto
slides, dewaxed in xylene, rehydrated in a graded ethanol
series, and prepared for immunoperoxidase staining accord-
ing to standard procedures. Primary antibodies included
anti-CD44v3 (1:100; Bender MedSystems, http://www.
bendermedsystems.com), anti–Ki-67 (1:20; Dako, http://www.
dako.com), anti-ﬁlaggrin (1:750; Abcam, http://www.
abcam.com), anti-loricrin (1:500; Abcam); anti-K14 (1:100;
Novocastra, http://www.novocastra.co.uk), and anti-CD31
(1:100; Dako). After staining with the primary reagent for 1
h at room temperature, sections were washed, incubated with
biotinylated afﬁnity-puriﬁed secondary antibody or with
biotinylated anti-CD44 (2.5 lg/ml; PharMingen, http://www.
bdbiosciences.com) or HA-binding protein (HABP, 25 ng/ml;
Seikagaku Kogyo, Japan, http://www.seikagaku.co.jp) for 30
min at room temperature, washed, and treated with avidin-
biotin-peroxidase for 30 min at room temperature. The
sections were then washed with buffer and incubated in
0.05% DAB (3,39-diaminobenzidine; Sigma) and 0.03% H2O2
in phosphate buffer at room temperature. Cryostat sections
(5 lm) of skin samples of mice treated with biotinylated HAF
were frozen in liquid nitrogen, mounted onto slides, air-
dried, and incubated with anti-vimentin antibody (1:20; Santa
Cruz Biotechnology, http://www.scbt.com) for 1 h at room
temperature. The sections were then washed and incubated
with biotinylated immunoglobulins for anti-vimentin anti-
body and then streptavidin-FITC (1:500; Invitrogen, http://
www.invitrogen.com) and streptavidin rhodamine (1:500;
Pierce Biotechnology, http://www.piercenet.com). All sections
were examined under a Zeiss axiophot microscope (http://
www.zeiss.com) using appropriate ﬁlters.
Hyaluronidase Digestion
Hyaluronidase treatment of tissues was performed by
incubating the tissue sections with 1.5 lg/ml bovine testicular
hyaluronidase (Sigma) in phosphate-buffered saline (PBS) for
5 h at 37 8C. The sections were then stained either with
colloidal iron or with HABP as described above. The
hyaluronidase digestion experiments also included negative
controls incubated under otherwise similar conditions but
lacking the enzyme. An HA-secreting mesothelioma section
was used as a positive control.
Epidermal and Cutaneous Thickness Measurements
Epidermal thickness of mice was measured by a graded
ocular and multiplied by ten to correct the scale. Cutaneous
thickness measurements of the healthy participants and
patients were performed using a skin ultrasound system
(Episcan; Longport, http://www.longportinc.com).
Cell Proliferation
Epidermal and dermal Ki-67
þ cells were counted in ten
ﬁelds per section at 403magniﬁcation; the average value was
calculated.
Western Blot Analysis
Frozen mouse epidermis or dermis and human biopsy
samples were incubated in extraction buffer containing 20
mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM EDTA, 1% SDS,
10% glycerol, and protease inhibitor cocktail (complete;
Boehringer, http://www.boehringer-ingelheim.com), minced,
polytron-homogenized, and sonicated on ice. Cell culture
extracts were treated with the same buffer. Homogenates
were spun in a microcentrifuge for 20 min, and the soluble
fraction was extracted and subjected to western blot analysis
with appropriate antibodies.
Samples were loaded in nonreducing SDS sample buffer,
subjected to electrophoresis, and transblotted onto 0.45 lm
pore–size nitrocellulose membrane. Antibodies used for
Western blot analysis were anti-CD44 standard (Bender
MedSystems); anti-CD44v3 (Bender MedSystems); anti–
MMP-7 (G-20; Santa Cruz Biotechnology); anti–pro-HB-EGF
(M-18; Santa Cruz Biotechnology); anti–HB-EGF neutralizing
antibody (R&D Systems, http://www.rndsystems.com); and
anti-erbB1 and anti-erbB4 (Santa Cruz Biotechnology).
Immunoprecipitation
Lysates were incubated overnight at 4 8C with anti-CD44
antibodies and protein AþG agarose beads (Pierce Biotech-
nology) in the presence of BSA and rat IgG. Elution of
antigen–antibody complex was performed in nonreducing
SDS sample buffer by heating 5 min at 95 8C. After
centrifugation for 3 min at 15,000g, supernatant was loaded
on a 10% polyacrylamide gel.
Quantification of CD44, HA, and erbB1
Quantiﬁcation of CD44, HA, and erbB1 in the skin samples
by an enzyme-linked binding protein assay was performed
using the sCD44 ELISA Kit (Bender MedSystems), the
Corgenix Hyaluronic Acid Quantitative Test Kit (Endotell,
http://www.endotell.ch), and the erbB1 ELISA Kit (Sigma),
respectively, according to the manufacturers’ instructions.
In Vitro Keratinocyte Proliferation Assay
Epidermal keratinocytes were isolated and cultured in 96-
well plates (Becton Dickinson, http://www.bd.com) as de-
scribed previously [16]. On day 2 of culture, HAFs, HAFi, or
HAFl (100 lg/ml), monoclonal anti-human amphiregulin (AR)
neutralizing antibody (100 ng/ml), monoclonal anti-human
erbB1 neutralizing antibody (isotype IgG1; 100 ng/ml), mouse
recombinant tissue inhibitor of metalloproteinase 3 (TIMP-3;
100 ng/ml), or human HB-EGF (5 ng/ml; R&D Systems), TPA (1
ng/ml; Sigma), and human EGF (50 ng/ml; Sigma), in the
presence or absence of anti–HB-EGF neutralizing antibody
(10 ng/ml; R&D Systems), was added to the cultures. Mouse
IgG1 was used as a control of anti-erbB1. Human ﬁbroblasts
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cultured in 96-well plates. Culture medium contained DMEM,
10% FCS, 1% antibiotics for the ﬁbroblasts; and M199, 10%
FCS, 1% antibiotics, glutamine, 1% heparin, 1% ECGS
(endothelial cell growth supplement; Upstate, http://www.
upstate.com), 1% hydrocortisone, and 1% vitamin C for the
HUVECs. On day 2 of culture, bFGF (1 ng/ml), VEGF (20 ng/
ml), or HAFi (100 lg/ml) was added to the cultures. On day 5
of culture, supernatants alone or with HAFi (100 lg/ml) were
added to the keratinocyte cultures (1:4 ratio). Later (48 h),
0.037 MBq of [
3H]thymidine (Amersham, http://www.
amersham.com) was added to each well. Isotope incorpora-
tion was evaluated 24 h later in a Beckman LS 1801 (http://
www.beckmancoulter.com). b counter (Beckman Coulter,
Fullerton, California). All experiments were done in triplicate
and repeated 5 times, and the results were expressed as the
mean of incorporated counts per minute for each condition
tested.
Results
HAFi Induce CD44-Dependent Keratinocyte Proliferation
and Skin Hyperplasia
Cultured keratinocytes from the dorsal skin of wt and
CD44
 /  DBA/1 mice were incubated with HAF generated
from high-molecular-weight HA by sonication, enzymatic
digestion, and size exclusion gel ﬁltration (Figure 1A).
Exposure to HAFi but not to HAFl or HAFs resulted in
increased keratinocyte proliferation (Figure 1B). Consistent
with the notion that the proliferative response to HA is CD44
mediated, HAFi failed to induce proliferation in CD44
 / 
keratinocytes (Figure 1C).
To verify that the inability of HAFi to induce proliferation
of CD44
 /  keratinocytes was indeed due to the lack of CD44
and not to a more general proliferation defect of these cells,
we assessed the response of CD44
 /  keratinocytes to phorbol
ester and EGF stimulation. CD44
 /  keratinocytes were
observed to mount a proliferative response to both mitogens,
albeit to a lesser degree than wt cells (Figure 1D). It would
therefore seem reasonable to attribute the complete lack of
keratinocyte response to HAFi to the absence of the HA
receptor CD44.
The stimulatory effect of HAFi was not limited to cultured
keratinocytes. Incubation of primary human ﬁbroblasts from
a healthy donor and HUVECs with HAFi at concentrations
that induced keratinocyte proliferation resulted in increased
proliferation of both cell types (Figure 1E and 1F).
To determine whether HA fragments may induce kerati-
nocyte proliferation in vivo, the effect of repeated local
administration of HAFi to the dorsal skin of wt and CD44
 / 
DBA/l mice was assessed. To control for possible strain
speciﬁc effects, SKH1 hairless mice were also subjected to
local HAFi treatment. Daily topical application of a solution
of 0.2% HAFi for 3 d resulted in signiﬁcant epidermal
hyperplasia (Figure 2A and 2B) that reﬂected increased cell
proliferation, as demonstrated by increased numbers of
epidermal and dermal Ki-67
þ cells, in all six wt but in none
of the six CD44
 /  mice tested (Figure 2C and 2D). Consistent
with the behavior of CD44
 /  keratinocytes in vitro, the skin
of CD44
 /  mice displayed moderate hyperplasia in response
to local phorbol ester application (Figure S1A and S1B),
supporting the notion that the complete lack of hyperplasia
in response to HAFi could be attributed to the absence of
CD44 itself.
The potential effect of HAFi on keratinocyte differ-
entiation in vivo was assessed by staining of HAFi- and
vehicle-treated skin sections with antibodies against differ-
entiation markers, including keratin-14, ﬁlaggrin, and lor-
icrin. All three differentiation markers were found to display
increased expression in hyperplastic HAFi-treated skin that
Figure 1. The Effect of HAF In Vitro
(A) Elution profile of HAF. HAFs, HAFi, or HAFl were run on a Sephacryl S-400 column after sonification and enzymatic digestion.
(B) HAFi, but not HAFs or HAFl, induces in vitro mouse keratinocyte proliferation that is inhibited by anti-erbB1 antibody and TIMP-3. Keratinocytes from
SKH1 and DBA/1 wt
 mice were cultured in 96-well plates. On day 5 of culture, HAFs, HAFi, or HAFl (100 lg/ml), monoclonal anti-human AR neutralizing
antibody (100 ng/ml), monoclonal anti-human erbB1 neutralizing antibody (isotype IgG1; 100 ng/ml), or mouse recombinant TIMP-3 (100 ng/ml) was
added to the cultures. Mouse IgG1 was used as a control for anti-erbB1. Later (48 h), 0.037 MBq of [
3H]-thymidine was added to each well. All
experiments were done in triplicate and repeated five times. The results are presented as the mean incorporated counts per min 6 standard error of
the mean (SEM) of three wells per group. ***p , 0.001 (HAFi and HAFiþanti-AR versus none; HAFiþanti-erbB1, HAFiþTIMP3, and mouse IgG1 versus
HAFi; Student’s t-test).
(C) In vitro proliferative response of mouse keratinocytes to HAFi is CD44 and HB-EGF dependent. Keratinocyte proliferation in response to HAFi in vitro.
Keratinocytes from SKH1, DBA/l wt, and DBA/l CD44
 /  mice were cultured in 96-well plates. On day 5 of culture, HAFi (100 lg/ml), human HB-EGF (50
ng/ml), or mouse anti-human HB-EGF–neutralizing antibody (100 ng/ml) was added to the cultures. Later (48 h), 0.037 MBq of [
3H]-thymidine was
added to each well. All experiments were done in triplicate and repeated five times. The results are presented as the mean incorporated counts per min
6 SEM of three wells per group. **p , 0.01; ***p , 0.001 (HB-EGF versus none; anti–HB-EGF þ HAFi versus HAFi; Student’s t-test).
(D) Keratinocyte proliferation in response to TPA and EGF in vitro. Keratinocytes from DBA/l wt and DBA/l CD44
 / mice were cultured in 96-well plates.
On day 5 of culture, TPA (1 ng/ml), EGF (50 ng/ml), or HAFi (100 lg/ml) was added to the cultures. Later (48 h), 0.037 MBq of [
3H]-thymidine was added
to each well. All experiments were done in triplicate and repeated five times. The results are presented as the mean incorporated counts per min 6 SEM
of three wells per group. **p , 0.01 versus none; ***p , 0.001 versus none (Student’s t-test).
(E) Fibroblast proliferation in response to bFGF in vitro. Human fibroblasts were cultured in 96-well plates. On day 2 of culture, bFGF (1 ng/ml) or HAFi
(100 lg/ml) was added to the cultures. Later (48 h), 0.037 MBq of [
3H]-thymidine was added to each well. All experiments were done in triplicate and
repeated five times. The results are presented as the mean incorporated counts per minute 6 SEM of three wells per group. ***p , 0.001 versus none
(Student’s t-test).
(F) Vascular endothelial cell proliferation in response to VEGF in vitro. HUVECs were cultured in 96-well plates. On day 2 of culture, VEGF (20 ng/ml) or
HAFi (100 lg/ml) was added to the cultures. Later (48 h), 0.037 MBq of [
3H]-thymidine was added to each well. All experiments were done in triplicate
and repeated five times. The results are presented as the mean incorporated counts per min 6 SEM of three wells per group. ***p , 0.001 versus none
(Student’s t-test).
(G) Keratinocyte proliferation in response to HAFi-treated fibroblast or HUVEC supernatants in vitro. Keratinocytes from DBA/l wt mice, fibroblasts, or
HUVECs were cultured in 96-well plates. On day 2 of culture, HAFi (100 lg/ml) was added to the fibroblast or HUVEC cultures. On day 5 of culture,
supernatants alone or supplemented with HAFi (100 lg/ml) were added to the keratinocyte cultures (1:4 ratio). Later (48 h), 0.037 MBq of [
3H]-thymidine
was added to each well. All experiments were done in triplicate and repeated five times. The results are presented as the mean incorporated counts per
min 6 SEM of three wells per group. ***p , 0.001 versus none (Student’s t-test).
doi:10.1371/journal.pmed.0030493.g001
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(A) HAFi-induced hyperplasia of mouse skin is CD44 dependent. Histological sections of vehicle-treated (a and c) or HAFi-treated (b and d) DBA/1 (a and
b) or CD44
 /  (c and d) dorsal mouse skin. Note the epidermal hyperplasia in DBA/1 but not in CD44
 /  mice.
(B) Epidermal thickness in vehicle- or HAFi-treated SKH1, DBA/1, and CD44
 / mouse back skin measured with an ocular micrometer. Ten measurements
were performed per mouse, and the average value was calculated. The results are presented as the mean epidermal thickness 6 SEM of six animals per
group. ***p , 0.001 versus vehicle (Student’s t-test).
(C) In vivo proliferative response of mouse epidermis to HAFi is CD44 dependent. Ki67 staining of vehicle-treated (a and c) or HAFi-treated (b and d)
DBA/1 (a and b) or CD44
 /  (c and d) dorsal mouse skin.
(D) Dermal cellularity in vehicle- or HAFi-treated SKH1, DBA/1, and CD44
 /  mouse back skin. Samples were counted at 403magnification. Ten counts
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Hyaluronate Reverses Skin Atrophywas proportional to the degree of hyperplasia (Figure S2A).
Thus, keratin-14 expression was observed throughout the
epidermis, whereas ﬁlaggrin and loricrin expression was
conﬁned to the granular layer, suggesting that HAFi
application had no obvious effect on keratinocyte differ-
entiation in vivo.
The effect of HAFi on the composition of the dermis was
assessed by addressing changes in collagen expression and
vascularization. Staining with Sirius red revealed an increase
in collagen content of the superﬁcial dermis (Figure S2B
[parts a and b]). Elastic ﬁber increase in the dermis was
revealed by van Gieson elastin staining (Figure S2B [parts c
and d]), and an increase in blood vessel content was observed
with anti-CD31 antibody (Figure S2B [parts e and f]),
reﬂecting the effect of HAFi on ﬁbroblasts and HUVECs
observed in vitro.
Finally, to determine whether HAFi-mediated stimulation
of ﬁbroblasts and endothelial cells might indirectly partic-
ipate in keratinocyte proliferation, keratinocytes derived
from wt mice were incubated with 1:4 diluted conditioned
culture media from 72-h HAFi- and vehicle-treated ﬁbro-
blasts and HUVECs. Neither HAFi-treated ﬁbroblasts nor
HUVEC culture supernatants displayed any signiﬁcant effect
on keratinocyte proliferation in vitro (Figure 1G). However,
supplementation of the 72-h HAFi-treated endothelial cell
and ﬁbroblast supernatants with 100 lg/ml of fresh HAFi
induced keratinocyte proliferation to a degree that was
similar to that when HAFi were directly added to keratino-
cyte cultures (Figure 1G), rendering unlikely the possibility
that nutrient depletion of the supernatants inhibited
proliferation. It would seem conceivable that the HAFi used
to stimulate endothelial cells and ﬁbroblasts had been
internalized and/or degraded by 72 h of culture, providing a
plausible explanation for the lack of keratinocyte stimulation
by the 72-h conditioned culture media. Taken together, these
observations suggest that HAFi-induced epidermal hyper-
plasia in vivo reﬂected a direct effect of HAFi on keratinocyte
proliferation, independent of ﬁbroblast and endothelial cell
stimuli.
Topical Application of HAFi Restores Atrophic Skin Lesions
in Humans
To assess the effect of HAFi administration to human skin,
six patients with atrophic skin lesions and 17 control
participants, including seven healthy men (age, 29–32 y;
mean age, 25.5 y) and ten healthy postmenopausal women
who had not received hormone replacement therapy (age, 55–
65 y; mean age, 60 y) were subjected to daily topical
application to the forearm of a 1% preparation of HAFi
for 1 mo. Following termination of the treatment, none of the
control participants revealed a measurable increase in skin
thickness, signs of inﬂammation, or scaling (Figure 2G [part
a]). By contrast, all six patients with skin atrophy that was
either age-related (three patients, aged 60–88 y; mean age, 76
y) or associated with corticosteroid therapy for rheumatoid
arthritis (three patients, aged 74–86 y; mean age, 81 y)
responded to topical HAFi application by developing marked
skin thickening (Figure 2E and 2F, and Figure 2G [part b]) at
the end of the treatment period. Most notably, pseudoscars
(representing the healing stage of hyperextended skin; Figure
2E, red arrows), hemorrhage (Figure 2E, yellow arrow), and
visible superﬁcial vessels (Figure 2E, blue arrow), all of which
are associated with skin atrophy, disappeared in response to
HAFi-mediated restoration of skin trophicity (Figure 2E and
2F). Contrary to HAFi, the same concentration of HAFl and
HAFs applied for the same duration to the six patients with
skin atrophy had no effect on skin thickness (unpublished
data).
HAFi Applied to the Skin Induce Expression of CD44 and
Enzymes Implicated in HA Metabolism
To begin to address the putative mechanism of HAFi-
induced skin hyperplasia, we assessed changes in CD44
expression and HA synthesis in response to local HA
application. Topical HAFi application, but not HAFl or
HAFs (unpublished data) application, resulted in increased
CD44 expression at the RNA and protein levels throughout
the epidermis (Figure 3A [parts a and b] and unpublished
data). HAFi also selectively increased CD44v3 isoform
expression in basal and suprabasal keratinocytes, with the
exception of the granular layer (Figure 3A [parts c and d]).
The superﬁcial dermis of HAFi-treated DBA/1 mouse
dorsal skin sections displayed strong reactivity with biotiny-
lated HABP, an established probe of tissue HA (Figure 3B),
which was abrogated by hyaluronidase pretreatment of the
tissue sections (unpublished data). An enzyme-linked binding
protein assay conﬁrmed the presence of increased amounts
of HA in the epidermis and dermis (Figure 3B [parts c and d]
and unpublished data) of HAFi-treated DBA/l and SKH1
hairless mice.
To address the fate of locally administered HAF to the skin,
size-fractionated HA was biotinylated, and its localization was
traced with ﬂuorescein-labeled streptavidin. Biotinylated
HAFs-treated SKHI hairless mice and, to a lesser extent,
HAFi- but not HAFl-treated SKH1 hairless mice displayed
biotin deposits in the superﬁcial dermis after 3 d of topical
application (Figure 3C). The observed biotin deposits were
removed by hyaluronidase treatment of the skin sections
(unpublished data), consistent with the notion that both
HAFs and HAFi can penetrate the epidermis. To further
assess HAFi localization in tissues, double staining using
biotinylated HAFi and ﬂuorescein-labeled streptavidin as well
were made per mouse, and the average value was calculated. The results are presented as the mean number of cells 6 SEM of six animals per group.
***p , 0.001 versus vehicle (Student’s t-test).
(E) HAFi corrects age- and corticosteroid-related atrophy in human skin. Atrophic human forearm skin 1 mo after topical treatment with vehicle (a) or
1% HAFi (b). Note the decrease of wrinkles, hemorrhage (yellow arrow), and pseudoscars (red arrows), the visibility of superficial vessels (blue arrow),
and the smoothening of the skin with after HAFi treatment.
(F) HAFi corrects age- and corticosteroid-related atrophy in human skin. Histology of atrophic human forearm skin 1 mo after topical treatment with
vehicle (a) or 1% HAFi (b). Note the significant epidermal hyperplasia after HAFi treatment.
(G) HAFi results in skin hyperplasia in atrophic but not normal human skin. Skin thickness in HAFi-treated young (a), nonlesional aged (b), or atrophic
aged (c) human skin measured by echography. The results are presented as boxplots with median values (triangles). Young untreated versus
nonlesional aged untreated, p , 0.001; young untreated versus atrophic aged untreated, p ¼ 0.001; atrophic aged untreated versus atrophic aged
treated, p , 0.01 (nonparametric Mann-Whitney U test).
doi:10.1371/journal.pmed.0030493.g002
PLoS Medicine | www.plosmedicine.org December 2006 | Volume 3 | Issue 12 | e493 2297
Hyaluronate Reverses Skin AtrophyPLoS Medicine | www.plosmedicine.org December 2006 | Volume 3 | Issue 12 | e493 2298
Hyaluronate Reverses Skin Atrophyas anti-vimentin antibody was performed. Colocalization of
HAFi and vimentin suggested internalization of HAFi by
mesenchymal dermal cells whose morphology was consistent
with that of ﬁbroblasts (Figure 3D and unpublished data).
HAFi were also observed in vimentin-negative acellular areas,
consistent with the extracellular matrix.
To determine whether the absorbed HAF might affect local
HA synthesis and degradation, we assessed the expression of
HA-polymerizing enzymes HAS1, HAS2, and HAS3 and the
major tissue HA-degrading enzyme, hyaluronidase 2 (Hyal2),
in HAFi-treated skin of DBA/1 and CD44
 /  mice (Figure 3E).
Northern blot analysis showed an increase in HAS1, HAS2,
HAS3, and Hyal2 transcripts in both wt and CD44
 /  skin,
suggesting that HAFi can induce both HA-producing and
-degrading enzymes in a CD44-independent manner.
HAFi-Mediated Keratinocyte Proliferation is HB-EGF and
EGFR Dependent
Because HAFi-induced CD44v3 expression (Figure 3A
[parts c and d]), we addressed the expression of molecules
reported to be recruited by CD44v3, particularly HB-EGF and
its receptors [13], in HAFi-treated mouse skin. HAFi-treated
DBA/l and SKH1 hairless epidermis displayed a robust
induction of CD44v3 and pro-HB-EGF (22–28 kDa) expres-
sion as well as a mild induction of erbB1 expression (Figures
4A and S3, and unpublished data). Importantly, cleaved (14–
19 kDa) HB-EGF species, corresponding to the active form,
appeared in lysates of HAFi-treated epidermis (Figure 4A). As
erbB4 is not expressed in mouse skin [17], erbB1 fulﬁls the
role of the principal HB-EGF receptor. To assess the physical
association between CD44 and erbB1, we performed coim-
munoprecipitation experiments. Consistent with observa-
tions showing interactions between CD44 and erbB4 [13], as
well as erbB2 and erbB3 [18], Western blot analysis using anti-
erbB1 antibody of anti-CD44 antibody immunoprecipitates
from lysates of cultured keratinocytes and epidermis of DBA/
1 mouse skin revealed that erbB1 coimmunoprecipitates with
CD44 (Figure 4B). It is noteworthy that the skin of patients
with atrophy displayed decreased CD44 and erbB1 expression
as well as reduced HA synthesis (Figure 4C).
Based on the observations that HAFi treatment enhanced
CD44v3, erbB1, and HB-EGF expression and induced HB-
EGF activation, we addressed the possibility that these
molecules may form part of the functional machinery
implicated in the regenerative response of keratinocytes to
HAFi. The proliferative response of wt DBA/1 mouse
keratinocytes to HAFi was abrogated by anti-human erbB1
neutralizing antibody (Figure 1B). Recombinant HB-EGF
stimulated robust proliferation of wt DBA/1 keratinocytes
but induced only mild proliferation of CD44-deﬁcient
counterparts, whereas AR, which does not bind CD44v3
[19], had no effect. Neutralizing anti–HB-EGF antibody
inhibited the HAFi-induced keratinocyte proliferation in wt
keratinocytes (Figure 1C), whereas an isotype-matched
unrelated antibody failed to do so. Because MMPs and the
related ADAM family proteases are implicated in proteolytic
activation of pro-HB-EGF, we tested the effect of the MMP
and ADAM (a disintegrin and metalloproteinase) inhibitor
TIMP-3 on HAFi-induced keratinocyte proliferation. Con-
sistent with the notion that MMPs [13] and ADAMs [20]
activate HB-EGF, recombinant TIMP-3 abrogated HAFi-
induced keratinocyte proliferation (Figure 1B).
Discussion
Our observations provide evidence for the ﬁrst time to our
knowledge that topically applied HAF ranging from 50,000 to
400,000 Da penetrate the epidermis and induce keratinocyte
proliferation that translates into the thickening of mouse and
human skin. Penetration of topically applied HA of 250,000–
400,000 Da into mouse and human dermis was recently
demonstrated [21]. Here we show that both HAFs and HAFi
penetrate mouse skin in vivo, but that only the HAFi induce
cellular proliferation within the epidermal and dermal
compartments.
At least two types of effects occurred as a result of topical
HAFi application: CD44-independent penetration of skin
and induction of HAS and Hyal2, and CD44-dependent
keratinocyte proliferation. Both ﬁbroblasts and endothelial
cells also proliferated in response to HAFi in vitro, providing
a possible explanation for the increased dermal collagen
deposition and angiogenesis, respectively, observed in vivo.
However, the contribution of ﬁbroblast activity and angio-
genesis to epidermal hyperplasia was most likely of minor
importance, given that conditioned culture media of HAFi-
stimulated ﬁbroblasts and endothelial cells failed to augment
keratinocyte proliferation. Importantly, an increase in
human skin thickness in response to HAFi was observed only
in patients with skin atrophy. Although the reasons of the
absence of such a response in healthy participants can only be
Figure 3. The Effect of HAF on CD44, HA, and HA-Polymerizing and -Degrading Enzymes, and Localization of HAF in Mouse Skin
(A) HAFi increases CD44 expression in mouse skin. Immunostaining of sections of vehicle-treated (a and c) or HAFi-treated (b and d) DBA/1 mouse
dorsal skin with anti-CD44 (a and b) or anti-CD44v3 (c and d) antibodies. Note the hyperplasia and increase in both CD44 and CD44v3 expression in the
epidermis.
(B) HAFi increases the epidermal and dermal HA content in mouse skin. HABP staining of sections of vehicle-treated (a) or HAFi-treated (b) DBA/1 mouse
dorsal skin showing elevated amounts of HA in the dermis. Epidermal (c) and dermal (d) HA content of HAFi-treated skin of SKH1 hairless mice were
quantified by an enzyme-linked binding protein assay. The results are presented as the mean HA concentration 6 SEM of six animals per group. **p ,
0.01 versus vehicle; *p , 0.05 versus vehicle (Student’s t-test).
(C) HAFs and HAFi penetrate mouse skin. Streptavidin-FITC staining of sections of vehicle (a), biotinylated HAFs-treated (b), HAFi-treated (c), or HAFl-
treated (d) SKH1 hairless mouse back skin. Note the presence of biotin in HAFs-treated, and to a lesser extent, in HAFi-treated skin (arrows).
(D) Topically applied HAFi is located both intra- and extracellularly. Sections of HAFi-treated dorsal SKH1 hairless mouse skin were stained with
streptavidin-FITC (a) or anti-vimentin antibody, biotinylated secondary antibody, and streptavidin-rhodamine (b). Topically applied HAFi (a; green
fluorescence, top arrows) shows colocalization (c; yellow fluorescence, arrows) with vimentin (b; red fluorescence, arrows) and outside the cells in the
extracellular matrix (a; lower arrows).
(E) HAFi increases the expression of HASs and Hyal2 in mouse skin. Northern blot analysis of HAS1, HAS2, HAS3, and Hyal2 RNA expression in vehicle- or
HAFi-treated DBA/1 wt or CD44
 /  mouse dorsal skin. The hybridization signals were quantitated by scanning the autoradiograms with a laser
densitometer. The results are presented as the mean optical density 6 SEM of three animals per group. *p , 0.05 versus vehicle; **p , 0.01 versus
vehicle (Student’s t-test).
doi:10.1371/journal.pmed.0030493.g003
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Hyaluronate Reverses Skin Atrophyspeculative at present, it is possible that physiological HA
production saturates tissue CD44 binding capacity in the
steady state, such that additional exogenous HA fragments
fail to induce a signiﬁcant CD44-dependent response. What-
ever the precise mechanism, the absence of skin hyperplasia
in healthy participants in response to HAFi suggests that
topical HAFi administration does not present the risk of
inducing undesirable local side effects.
Penetration of HA fragments into the dermis may occur via
hair follicles, which provide a well-recognized route for
macromolecular skin penetration [22] and could explain the
dermal localization of HAFs and HAFi. However, the increase
in dermal HA content of HAFi- and HAFs-treated hairless
SKH1 mouse skin, which contains incompletely developed
and partially functional follicles [22], leaves open the
possibility for the participation of an additional putative
mechanism of size-limited HAF penetration, including
possibly passive absorption. HAFi was observed to induce
HAS expression consistent with the possibility that increased
local HA synthesis may contribute to the increased HA
content. The mechanism whereby HAFi might induce local
HAS and hyaluronidase expression is unknown. Keratino-
Figure 4. The Effect of HAF on CD44v3, pro-HB-EGF, and HB-EGF in Mouse Skin; CD44 and erbB1 Association In Vitro and In Vivo; CD44, HA, and erbB1
Levels in Young and Elderly Skin
(A) HAFi induces expression of CD44v3, pro-HB-EGF, and active HB-EGF in mouse skin. Western blot analysis on the protein extracts of vehicle- or HAFi-
treated SKH1 hairless mice for CD44v3 (;200 kDa [a]), active HB-EGF (;15 kDa [b]), pro-HB-EGF (;25 kDa [c]), and loading control a-tubulin (50 kDa [d]).
(B) CD44 associates with erbB1 in keratinocytes in vitro and in vivo. Western blot analysis of anti-CD44 antibody immunoprecipitates of protein extracts
of cultured keratinocytes (a) or epidermis of DBA/1 mouse skin immunoblotted with anti-erbB1. Mock, isotype-matched rat IgG; beads, protein AþG
agarose beads treated with anti-CD44 antibody.
(C) CD44, HA and erbB1 levels are diminished in atrophic human skin. CD44 (a), HA (b), and erbB1 (c) expression in forearm skin biopsy specimens of
young adults (control) and elderly patients with skin atrophy. The results are presented as the mean CD44, HA, or erbB1 concentration 6 SEM of three
subjects per group. *p , 0.05 versus young controls (Student’s t-test).
doi:10.1371/journal.pmed.0030493.g004
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Hyaluronate Reverses Skin Atrophycytes and ﬁbroblasts provide the principal source of HA in
the epidermis and dermis, respectively [23], and control local
HA metabolism. CD44 is believed to play a major role in the
uptake of HA by receptor-mediated endocytosis [24] in both
cell types. Following internalization, HA undergoes intra-
cellular degradation that is possibly mediated by endosomal/
lysosomal hyaluronidases [25]. HAF released by keratinocytes
traverse the basement membrane to the dermis, where they
are cleared via lymphatic vessels [26]. It would appear that
mechanisms independent of CD44 might sense changes in
local HA concentration, or that HAFi stimulate receptors
other than CD44 to induce HAS and hyaluronidase expres-
sion. Increased tissue HA concentration typically occurs in
the context of development, injury, and tumor growth, and is
believed to actively participate in the process of tissue
remodeling. It is conceivable that an increase in tissue HA,
whether of endogenous or exogenous origin, is interpreted by
local ﬁbroblasts to reﬂect a remodeling process, triggering
additional HA synthesis and degradation.
Proliferation in response to HAFi is a CD44-dependent
event. Our present observations provide evidence that in
addition to CD44, HB-EGF, erbB1, and MMPs/ADAMs are
required for HA-dependent in vitro keratinocyte prolifer-
ation. The absence of a proliferative response of CD44
 / 
keratinocytes to HB-EGF is consistent with the notion that
HB-EGF interaction with its receptors requires presentation
by heparan sulfate side chains of CD44v3-containing isoforms
[19]. Similar to other members of the EGF family, pro-HB-
EGF is expressed as an integral membrane protein of 22–28
kDa [27], which, following stimulation of cells with mitogens,
undergoes MMP-mediated release of mature soluble 14–19
kDa HB-EGF [28]. Accordingly, topical application of HAFi
oligosaccharide resulted in a signiﬁcant increase in pro-HB-
EGF and HB-EGF, while inhibition of MMP activity by TIMP-
3 abrogated the corresponding proliferative response.
The observation that anti-erbB1– and anti–HB-EGF–block-
ing antibodies had the same abrogating effect as the absence
of CD44 on in vitro keratinocyte proliferation in response to
HAFi supports the notion that erbB1 signaling, triggered by
HB-EGF, may play a key role in HAFi-induced proliferation.
Similar to its role in uterine and mammary epithelia, HA-
induced CD44v3 aggregates may recruit a functional cell-
surface complex in keratinocytes composed of pro-HB-EGF,
erbB1, which replaces erbB4, and an MMP or ADAM [13,20].
MMP/ADAM-mediated proteolytic cleavage of HB-EGF and
CD44-mediated presentation of mature HB-EGF to erbB1
may then induce proliferation (Figure 5).
Our observations have deﬁned 50,000–400,000 Da HAF as
Figure 5. Hypothetical Assembly of the CD44v3/HB-EGF/erbB1 Complex and the Mechanism of HAFi-Induced Keratinocyte Proliferation
(A) CD44, HA, and HB-EGF in normal skin (a), atrophic skin (b), and following treatment of atrophic skin treated with HAFi (c).
(B) Schematic representation of the hypothetical assembly of the putative complex: HAFi mediates CD44v3 and heparan sulfate–bound pro-HB-EGF
aggregation, resulting in the recruitment and activation of an MMP/ADAM. Pro-HB-EGF is cleaved by the MMP/ADAM, and the resulting active moiety
binds and activates erbB1, generating proliferation signals.
doi:10.1371/journal.pmed.0030493.g005
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Hyaluronate Reverses Skin Atrophyreagents capable of inducing a proliferative response in
mouse and human skin. Clinically, topical HAFi application
resulted in epidermal hyperplasia with restoration to normal
thickness of atrophic human skin as early as 1 mo after
initiation of treatment. This effect was accompanied by
signiﬁcant clinical improvement, suggesting that HAFi may
provide the basis for the development of novel therapeutic
strategies for skin diseases characterized by atrophy.
Supporting Information
Figure S1. The Effect of TPA on CD44
 /  Mouse Skin
(A) TPA induces a reduced skin hyperplasia in CD44
 /  mice.
Histological sections of acetone-treated (parts a and c) or TPA-
treated (parts b and d) DBA/1 (parts a and b) or CD44
 /  (parts c and
d) dorsal mouse skin. Note the decreased epidermal hyperplasia in
CD44
 /  mice.
(B) Epidermal thickness in acetone- or TPA-treated DBA/1 and
CD44
 /  mouse back skin measured with an ocular micrometer. Ten
measurements were performed per mouse, and the average value was
calculated. The results are presented as the mean epidermal thickness
6 SEM of six animals per group. ***p , 0.001 versus acetone
(Student’s t-test).
Found at doi:10.1371/journal.pmed.0030493.sg001 (293 KB JPG).
Figure S2. The Effect of HAFi on Mouse Epidermal Differentiation
and Atrophic Human Dermis
(A) HAFi has no effect on epidermal differentiation in mouse skin.
Immunostaining of sections of vehicle-treated (parts a, c, and e) or
HAFi-treated (parts b, d, and f) DBA/1 mouse dorsal skin with anti-
K14 (parts a and b), anti-ﬁlaggrin (parts c and d), or anti-loricrin
(parts e and f) antibody. Note the lack of increase in staining intensity
despite the increased number of stained cells in HAFi-treated skin.
(B) HAFi increases the collagen, elastin and vascular content in
atrophic human skin. Histology of atrophic human forearm skin 1
month after topical treatment with vehicle (part a) or 1% HAFi (part
b), stained with Sirius red (parts a and b), van Gieson elastin (parts c
and d), or anti-CD31 antibody (parts e and f). Note the increase in
dermal collagen, elastic ﬁbers, and vessels after HAFi treatment.
Found at doi:10.1371/journal.pmed.0030493.sg002 (882 KB JPG).
Figure S3. HAFi Induces Expression of CD44v3 in Mouse Skin
Western blot analysis on the protein extracts of vehicle- or HAFi-
treated SKH1 hairless mice for CD44v3.
Found at doi:10.1371/journal.pmed.0030493.sg003 (454 KB JPG).
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Hyaluronate Reverses Skin AtrophyEditors’ Summary
Background. Time wreaks many changes in the human body but the
skin is where one of the first visible signs of aging—wrinkles—occurs.
The skin consists of three main layers. The outermost layer is the
epidermis. It is the thickness of a sheet of paper and forms a barrier that
prevents the body losing water or infectious agents entering it. The cells
in the epidermis are mainly keratinocytes. These specialized skin cells are
continually produced at the base of the epidermis. From there, they
move toward the skin’s surface where they are shed. The middle layer is
the dermis. It is about ten times thicker than the epidermis and contains
the blood vessels that feed the skin, nerves, sebaceous glands, and hair
follicles. The final, subcutaneous layer contains sweat glands, some hair
follicles, blood vessels and fat. The dermis contains collagen fibers that
support the skin and elastin fibers that provide flexibility. Human skin
begins to age in early adulthood. By the time a person is 80 years old,
their epidermis may be half its original thickness because of decreased
keratinocyte proliferation. The dermis also thins, and loss of collagen and
elastin fibers means that the skin becomes less elastic. The gradual loss
of epidermis and dermis—skin atrophy—is clinically important because
aging skin is more fragile and heals slower than young skin and is also
prone to ulceration.
Why Was This Study Done? No one knows why skin atrophy occurs, but
it is becoming more common as people live longer, and there is no
effective treatment for it. One characteristic of atrophic skin is that,
compared to normal skin, it contains less hyaluronate (also called
hyaluronan and hyaluronic acid)—a large carbohydrate component of
the extracellular matrix, the material that surrounds cells. It also contains
less CD44, a cell-surface protein that interacts with hyaluronate. This
interaction can stimulate cell proliferation and migration. Given these
observations, in this study the researchers have investigated whether
treating atrophic skin with fragments of hyaluronate might counteract
atrophy.
What Did the Researchers Do and Find? The researchers isolated
keratinocytes from normal mice and from CD44-deficient mice (CD44
 / 
mice) and treated them with different sized fragments of hyaluronate.
Intermediate sized hyaluronate fragments (so-called HAFi) but not large
or small fragments increased the proliferation of normal keratinocytes
but not CD44
 /  keratinocytes. This suggests that proliferation in
response to HAFi is CD44-dependent. Similarly, a cream of HAFi applied
to the backs of normal mice caused thickening of the epidermal layer but
had no effect on CD44
 /  mice. Finally, topical application of HAFi for
one month caused skin thickening and clinical improvement in six
people with skin atrophy but had no effect on normal human skin. The
collagen, elastic fiber, and blood vessel content of the dermis also
increased in treated patients. By using antibodies to block the function
of various proteins, the researchers also discovered that heparin-binding
epidermal growth factor (HB-EGF, a protein that stimulates keratinocyte
proliferation), erbB1 (a cell-surface protein that binds HB-EGF), and
matrix metalloproteinases (proteins that activate HB-EGF) are all required
for the stimulation of keratinocyte proliferation by HAFi.
What Do These Findings Mean? Taken together, these results provide
the first indication that application of HAFi to atrophic skin might be
useful therapeutically. The absence of any effect on normal human skin is
reassuring but puzzling given the thickening seen in normal mouse skin,
so this finding needs confirmation before hyaluronate fragments are
used clinically. Longer trials in more people are also needed to
characterize the clinical effects fully. Finally, the mechanism by which
hyaluronate fragments have their effect needs to be studied in more
depth. Such studies might reveal other potential therapeutic options for
the treatment of skin atrophy.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030493.
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